Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
TREM2 is a receptor for lipids expressed in microglia. The R47H variant of human TREM2 impairs ligand binding and increases Alzheimer’s disease (AD) risk. In mouse models of amyloid β (Aβ) accumulation, defective TREM2 function affects microglial response to Aβ plaques, exacerbating tissue damage, whereas TREM2 overexpression attenuates pathology. Thus, AD may benefit from TREM2 activation. Here, we examined the impact of an anti-human TREM2 agonistic mAb, AL002c, in a mouse AD model expressing either the common variant (CV) or the R47H variant of TREM2. Single-cell RNA-seq of microglia after acute systemic administration of AL002c showed induction of proliferation in both CV- and R47H-transgenic mice. Prolonged administration of AL002c reduced filamentous plaques and neurite dystrophy, impacted behavior, and tempered microglial inflammatory response. We further showed that a variant of AL002c is safe and well tolerated in a first-in-human phase I clinical trial and engages TREM2 based on cerebrospinal fluid biomarkers. We conclude that AL002 is a promising candidate for AD therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AL002 (27) is a TREM2-specific monoclonal antibody that activates TREM2 to enhance microglial function, thereby reducing Aβ plaque formation and attenuating neurite dystrophy.474”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [474]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“enhancing TREM2 signaling by TREM2 agonist antibody, direct delivery of the TREM2 gene, or stimulating other pathways to increase TREM2 expression in the brains of AD mice enhanced Aβ phagocytosis and improved cognitive behaviors.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging evidence has shown that TREM2 activation increased Aβ phagocytosis, relieved neuroinflammation, and improved cognitive behavior in AD mouse models.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an AD mouse model, administration of AL002c, a variant of the AL002 antibody, attenuated tau plaques and neurite dystrophy, improved behavior, and reduced microglial inflammation.537”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [537]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The opposite phenotypes observed in PLCG2 KO iMGs and Plcγ2-P522R KI mice also support the notion to therapeutically stimulate TREM2 functions [6, 16, 17, 43].”
From The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions (2020) · cites this paper as [17]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Self-citationDissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
ATP mediates rapid microglial response to local brain injury in vivo
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., Dustin, M. L., & Gan, W.-B. (2005) · Nature Neuroscience · doi:10.1038/nn1472 · Cited by 3,913
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“In this model, plaques become clearly detectable at 3–4 mo of age and continue to grow for several months (Oakley et al., 2006).”
MethodAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Single-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568
Cited by
Items 301–400 of 579
TREM2 in Regulating Macrophage Inflammatory Responses and Disease Pathogenesis
Medd, M. M. (2024) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2024054889 · Cited by 14
Tau Accumulation Induces Microglial State Alterations in Alzheimer's Disease Model Mice
Nagata, K., Hashimoto, S., Joho, D., Fujioka, R., Matsuba, Y., Sekiguchi, M., Mihira, N., Motooka, D., Liu, Y., Okuzaki, D., et al. (2024) · eNeuro · doi:10.1523/eneuro.0260-24.2024 · Cited by 13
RhoA/ROCK/GSK3β Signaling: A Keystone in Understanding Alzheimer’s Disease
Medd, M. M., Yon, J. E., & Dong, H. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47020124 · Cited by 14
Duggan, M. R., Yang, S., Gómez, G., Cui, Y., Capuano, A. W., Chen, J., Yang, Z., Wen, J., Erus, G., Drouin, S. M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt7176 · Cited by 13
Kang, X., Tian, J., Shu, Q., Cheng, T., Wang, S., & Hu, Y. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.07.019 · Cited by 12
Self-citationArsenault, R., Marshall, S., Salois, P., Li, Q., & Zhang, W. (2024) · Biology · doi:10.3390/biology13020087 · Cited by 17
Deng, X., Qiu, Z., Chen, X., Liu, J., Wang, X., Li, J., Zhang, J., Cui, X., Fu, Y., & Jiang, M. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176859 · Cited by 11
Pavešković, M., De-Paula, R. B., Ojelade, S. A., Tantry, E. K., Kochukov, M. Y., Bao, S., Veeraragavan, S., Garza, A. R., Srivastava, S., Song, S., et al. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae115 · Cited by 11
Novel insights into the role of TREM2 in cerebrovascular diseases
Awuah, W. A., Ben-Jaafar, A., Kong, J. S. H., Sanker, V., Shah, M. H., Poornaselvan, J., Frimpong, M., Imran, S., Alocious, T., Abdul-Rahman, T., et al. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149245 · Cited by 12
Datta, D., & Arnsten, A. F. T. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14477 · Cited by 11
Xu, B., Tang, C., Han, R., Zhu, C., Yang, Y., Li, H. J., Wu, N., & He, D. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251326044 · Cited by 14
Li, J., Yu, X., Yang, D., Chen, S., Xu, J., Ma, S., Huang, C., Xu, B., Xue, L., & Wang, Y. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10250-1 · Cited by 11
Ye, Q., Gao, W., Feng, J., Li, X., Li, J., Yang, F., Li, L., Zi, M., Wu, X., Gao, H., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71185 · Cited by 11
Suk, K. (2026) · Experimental Neurology · doi:10.1016/j.expneurol.2026.115737 · Cited by 13
Matuszewska, M., Cieślik, M., Wilkaniec, A., Strawski, M., & Czapski, G. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010013 · Cited by 11
Azizan, Z., Bazrgar, M., Bazgir, N., Moini, S. H., Ghaseminejad‐Kermani, S., Safa, K., Eshaghian‐dorcheh, A., & Harirchian, M. H. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70269 · Cited by 10
Sobczuk, J., Paczkowska, K., Andrusiów, S., Bolanowski, M., & Daroszewski, J. (2024) · Biomolecules · doi:10.3390/biom14080918 · Cited by 10
Augusto‐Oliveira, M., Tremblay, M., & Verkhratsky, A. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_6 · Cited by 10
Role of astroglia and microglia in Alzheimer's disease and multiple therapeutic interventions
Li, L., Wang, Y., Feng, Q., Ma, C., He, C., Wan, W., & Tang, L. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251335572 · Cited by 11
Glucose Metabolism, Lactate, Lactylation and Alzheimer’s Disease
Hai, S., Hou, Y., Zhang, M., Gao, X., Yang, T., Shang, X., & Sun, X. (2025) · Aging and Disease · doi:10.14336/ad.2025.0338 · Cited by 14
Insights into Biomarkers of Alzheimer's Disease: From Core Markers to Emerging Directions
Zhu, W., Wang, Y., Qin, M., Zhao, Q., Feng, L., & Li, M. (2025) · Aging and Disease · doi:10.14336/ad.2025.0761 · Cited by 16
Behroozi, Z., Askarpour, H., & Baghcheghi, Y. (2026) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823261415807 · Cited by 12
Crosstalk between peripheral immunity and central nervous system in Alzheimer’s disease
Yang, H.-C., Qin, Q., Wang, M., Yin, Y., Li, R., & Tang, Y. (2023) · Cellular Immunology · doi:10.1016/j.cellimm.2023.104743 · Cited by 12
Yu, Z., Liu, J., Liu, Z., Liu, X., Tuo, J., Li, J., Tu, Y., Tan, Q., Ma, Y., Bai, Y., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14402 · Cited by 13
Roles of Microglia in AD Pathology
Gao, R., Wu, H., Li, Q., & Zhao, J. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230203112351 · Cited by 10
A TREM2 antibody energizes microglia
Zhao, N., & Bu, G. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01265-z · Cited by 16
Wei, C., Liu, J., Wu, B., Shen, T., Fan, J. J., Lin, Y., Li, L., Guo, Y., Shang, Y., Zhou, B., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.04.034 · Cited by 10
Glial Cells in Alzheimer’s Disease: Pathogenic Mechanisms and Therapeutic Frontiers
Sil, M., Mukherjee, N., Chatterjee, I., Ghosh, A., & Goswami, A. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02379-8 · Cited by 10
Proteostasis and Neuroinflammation in Alzheimer’s Disease
Potokiri, A., & Wang, H. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin39826 · Cited by 10
Synthetic cleavage-resistant TREM2 boosts macrophage efferocytosis to treat inflammatory diseases
Dong, X., Zhao, X., Gao, J., Bo, L., Li, Y., Kong, Z., 孙维绎, Xu, X., Liu, Z., Xiu, Q., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102580 · Cited by 15
Zhao, K.-P., Wang, X., Shao, M.-Q., He, C.-Y., & Yuan, F. (2023) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320231184988 · Cited by 9
Jang, B.-K., Shin, S. J., Park, H. H., Kumar, V., Park, Y., Kim, J. Y., Kang, H., Park, S. Y., Kwon, Y., Shin, S.-E., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics17010013 · Cited by 9
Wang, F., Liang, Y., & Wang, Q. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01646-x · Cited by 9
Gu, D., Wang, L., Zhang, N., Wang, H., & Yu, X. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02750-9 · Cited by 11
Friend turned foe: TREM2 agonist in battles against tau
Carling, G., Luo, W., & Gan, L. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20221850 · Cited by 8
Building a potent TREM2 agonistic, biparatopic, common light chain antibody
Almeida, A. R., Geddie, M. L., Bhate, A., Quan, C., Arndt, J. W., Jiao, Y., Santoro, J. C., Noiman, L., Vijayakumar, R., Sanchez-Salazar, J., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2546554 · Cited by 8
Ebrahimi, R., Bordbar, S., Azad, G., Davoody, S., Mahmoudi, M., & Esmaeilpour, K. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08403-4 · Cited by 10
Immunotherapies for Aging and Age-Related Diseases: Advances, Pitfalls, and Prospects
Yang, M., Wu, S., Zhang, J., Lu, L., Deng, D., Xia, Q., Lovell, J. F., Shi, X., & Jin, H. (2025) · Research · doi:10.34133/research.0866 · Cited by 12
Wu, J., Geng, C., Liu, L., & Tang, Y. (2025) · Medicine Plus · doi:10.1016/j.medp.2025.100112 · Cited by 9
Liao, Y., Mu, G., Deng, S., Lu, B. F., & Zheng, M. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07604-x · Cited by 9
Firdous, S. M., Chakrabortty, S., Undale, V., Mallik, S., & Gouda, M. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02169-7 · Cited by 9
Zhang, Y., Guo, X., Zhao, J., Gao, X., Zhang, L., Huang, T., Wang, Y., Niu, Q. L., & Zhang, Q. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.117107 · Cited by 8
Rueda‐Carrasco, J., & Hong, S. Y. (2020) · Trends in Neurosciences · doi:10.1016/j.tins.2020.08.002 · Cited by 8
Phadke, L., Lau, D. H. W., Aghaizu, N. D., Ibarra, S., Navarrón, C. M., Granat, L., Magno, L., Whiting, P. J., & Jolly, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1056067 · Cited by 9
Wang, Z.-T., Fu, Y., Chen, S., Huang, Y., Ma, Y., Wang, Y., Tan, L., & Yu, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14129 · Cited by 9
Chen, G., Han, M., Chen, Y., Lei, Y., Li, M., Wang, L., Wang, C., Hu, Y., Niu, J., Yang, C., et al. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2203072 · Cited by 9
Soluble CSF1R promotes microglial activation and amyloid clearance in Alzheimer’s disease
Zhang, L., Chen, K., Zeng, R., Bu, G., & Chen, X.-F. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03558-5 · Cited by 7
“While sCSF1R has been detected in peripheral circulation and cerebrospinal fluid (CSF) [31–33], its regulatory mechanisms and functional consequences—particularly in the CNS—remain poorly understood.”
The Role of TREM2 After Stroke: From Mechanisms to Therapeutic Potential
Zhou, T., Chen, A., Sun, Y., Huang, B., Xu, Y., & He, Q. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05622-w · Cited by 7
Singh, A. S., Naqvi, A. R., & Chanu, M. T. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.01.050 · Cited by 7
Advances in the drug treatment of Alzheimer’s disease: pathophysiology and mechanisms of action
Nowell, J., Crook, H., de Leon, M. J., & Edison, P. (2026) · BMJ · doi:10.1136/bmj-2023-078881 · Cited by 8
Molecular and Therapeutic Targets for Amyloid-beta Plaques in Alzheimer's Disease: A Review Study
Thomas, J., & WILSON, S. K. (2021) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.2021.3522.1 · Cited by 7
Bhardwaj, J. S., Paliwal, S., Singhvi, G., & Taliyan, R. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123089 · Cited by 9
Translational regulation and protein-coding capacity of the 5′ untranslated region of human TREM2
Yanaizu, M., Adachi, H., Araki, M., Kontani, K., & Kino, Y. (2023) · Communications Biology · doi:10.1038/s42003-023-04998-6 · Cited by 7
Endothelial senescence alleviates cognitive impairment in a mouse model of Alzheimer 's disease
Horibe, S., Emoto, T., Mizoguchi, T., Tanaka, T., Kawauchi, S., Sasaki, N., Yamashita, T., Ikeda, K., Emoto, N., Hirata, K., et al. (2023) · Glia · doi:10.1002/glia.24461 · Cited by 11
An insight into Alzheimer’s disease and its on-setting novel genes
Vigneswaran, J., Muthukumar, S. A., Shafras, M., & Pant, G. (2021) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-021-00420-2 · Cited by 8
Crosstalk between the aging intestinal microflora and the brain in ischemic stroke
Pluta, R. M., Jabłoński, M., Januszewski, S., & Czuczwar, S. J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.998049 · Cited by 7
GPR34 regulates microglia state and loss-of-function rescues TREM2 metabolic dysfunctionPreprint
Raju, K., Joy, D. A., Guldberg, S. M., Germain, K., Gould, N. S., Ha, C., Tatarakis, D., Dugas, J. C., Davis, S. S., Reeves, A. G., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.28.646038 · Cited by 7
Zheng, Q., Han, Y., Fan, M., Gao, X., Ma, M., Xu, J., Liu, S., & Ge, J. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.11904 · Cited by 6
Shrivastava, P., Lu, Y., Su, S., Kobayashi, Y., Zhao, Y., Lien, N., Masoud, A., Lukiw, W. J., & Hong, S. (2024) · Biomedicines · doi:10.3390/biomedicines12122865 · Cited by 6
Zhu, Q., Song, Y., Qian, Y., Zhang, R., Xue, J., & Hou, Y. (2025) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2025.25 · Cited by 10
Synergistic potential of TREM2 agonists and exercise training in Alzheimer’s disease
Zhang, J., Schneider, B. A., Muguerza, E., Chung, E. K., & Hsu, C. G. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00124.2025 · Cited by 6
Quipildor, G. F., Belfiore, R., Althobaiti, K., Najarzadeh, Z., Glabe, C. C., Readhead, B. P., Gandy, S., Salton, S. R., & Ehrlich, M. E. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-025-00012-x · Cited by 6
Nair, V. S., Plazzi, G., & Tucci, V. (2026) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2026.102283 · Cited by 6
Wang, X., Rong, Z., & Xue, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27115020 · Cited by 7
Zhai, L., Shen, H., Wu, S., Guo, L., Yang, Y., Sheng, J., & Han, C. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114284 · Cited by 7
Drug screening targeting TREM2-TYROBP transmembrane binding
Cobas-Carreño, M., Esteban-Martos, Á., Tomás‐Gallardo, L., Iribarren, Í., Gonzalez-Palma, L., Rivera-Ramos, A., Elena-Guerra, J., Alarcón‐Martín, E., Ruiz, R., Bravo, M. J., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01229-y · Cited by 6
Spinal cord injury regulates circular RNA expression in axons
Siddiq, M. M., Toro, C. A., Johnson, N. P., Hansen, J., Xiong, Y., Mellado, W., Tolentino, R. E., Johnson, K., Jayaraman, G., Suhail, Z., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1183315 · Cited by 6
The late-onset Alzheimer’s disease risk factor RHBDF2 is a modifier of microglial TREM2 proteolysis
Jocher, G., Müller, S. A., Hsia, H., Osua, M. L., Özcelik, G., Hofmann, L. I., Aßfalg, M., Dinkel, L., Feng, X. M., Schlepckow, K., et al. (2025) · Life Science Alliance · doi:10.26508/lsa.202403080 · Cited by 6
Advances in the Study of APOE and Innate Immunity in Alzheimer’s Disease
Li, Y., Chang, J., Chen, X., Liu, J., & Zhao, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230179 · Cited by 6
Race and Alzheimer Disease Biomarkers: A Neglected Race
Lleó, A., & Suárez-Calvet, M. (2021) · Neurology Genetics · doi:10.1212/nxg.0000000000000574 · Cited by 5
“In summary, the study by Schindler et al., adds on an important and under-investigated aspect of AD.”
BackgroundInfluentialAmyloid‐Related Imaging Abnormality (ARIA) Beyond the APOE‐ε4 Allele
Besin, V., Humardani, F. M., Yudiarto, F. L., Ong, P. A., Putra, S. E. D., & Ningrum, R. A. (2025) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70006 · Cited by 6
Application of computational methods in the drug discovery and development of Alzheimer's disease
Zhang, Q., Gong, X., Liu, H., & Yao, X. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.038 · Cited by 9
Biomarkers in CNS Drug Discovery, Drug Development, and Clinical Implementation
Caro, V. D., Williams, C., North, H. A., & Hamby, M. E. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch7 · Cited by 5
Bone-Derived Factors: Regulating Brain and Treating Alzheimer’s Disease
Guan, Q., Cao, Y., Zou, J., & Zhang, L. (2025) · Biology · doi:10.3390/biology14091112 · Cited by 9
Feng, X., & Wang, H. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00484 · Cited by 5
Shu, J., Liang, J., Zeng, L., Zhong, S., Fang, X., Xu, Y., Wu, Y., & Huang, X. (2025) · Advanced Science · doi:10.1002/advs.202508938 · Cited by 6
Akinluyi, E. T., Takahashi, K., Connolly, M. G., Poon, W. W., & Macauley, M. S. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00805 · Cited by 5
Hou, K., An, Z., Xu, Y., Wang, J., Zhou, M., Liu, Y., Zhu, X., & Wei, J. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-025-01247-x · Cited by 5
Zhang, Y., Pei, Z., Wen, Z., Chen, Y., Wang, H., Tan, W., Chen, X. Y., Liu, J., & Ni, Q. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1706384 · Cited by 5
Uemura, K., Hiro, S., Attachaipanich, S., Du, R., Yusof, N. I. S. M., Kinoshita, M., Hikosaka, M., & Ohtsuki, G. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1669272 · Cited by 7
Chen, B., Lu, H.-C., Huang, L., Wang, J., Bujold, M., Tang, L., Du, X., & Wang, Y. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03733-2 · Cited by 6
Kumari, A., & Zeng, X.-A. (2026) · Nutrients · doi:10.3390/nu18060907 · Cited by 6
Li, X., Wang, X., Dou, J., Wang, J., & Xue, F. (2026) · Cells · doi:10.3390/cells15131208 · Cited by 5
Primate cerebrospinal fluid CHI3L1 reflects brain TREM2 agonism
Schauer, S. P., Cho, C. H., Novikova, G., Roth, G. A., Lee, J., Sharma, A. D., Foley, A. R., Ng, C., Shen, P., Choi, M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13921 · Cited by 5
Yang, D., Chen, F., Ren, J., Wang, L., Zhu, Z., Wu, Z., Jin, Q., Luo, Y., Huang, H., Zhu, B., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12779-2 · Cited by 5
Toledano‐Díaz, A., Álvarez, M. I., & Tolédano, A. (2022) · Journal of Central Nervous System Disease · doi:10.1177/11795735221123896 · Cited by 5
Suri, K., Ramesh, M., Bhandari, M., Gupta, V., Kumar, V., Govindaraju, T., & Murugan, N. A. (2024) · ChemBioChem · doi:10.1002/cbic.202400224 · Cited by 5
Curtis, D., Joseph, S., & Initiative, T. A. D. N. (2025) · Journal of Neurogenetics · doi:10.1080/01677063.2025.2561589 · Cited by 4
Pathomechanisms, genetic insights, and therapeutics in diabetes-associated dementia
Meher, R., Sahu, R., Ranajit, S. K., Swain, T. R., Acharya, B., Feehan, J., Sahu, P. K., & Apostolopoulos, V. (2025) · Journal of Endocrinology · doi:10.1530/joe-25-0016 · Cited by 6
Advances in Diagnostics and Treatments for Alzheimer’s Disease
Sunderland, A., Thatcher, A. L., Rackley, E. V., & Kuruvilla, T. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2025.0492 · Cited by 4
Wan, S., Ji, X., Meng, R., & Li, M. N. (2025) · Revista de Neurología · doi:10.31083/rn46121 · Cited by 4
Yang, Z., Zhang, M., Zhi, W., Lizhen, Hu, X., Zou, Y., & Wang, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031492 · Cited by 4
Gaudet, A. D., & Fonken, L. K. (2026) · Trends in Neurosciences · doi:10.1016/j.tins.2026.01.002 · Cited by 6
Li, Y., Wang, Y., Li, H., Gao, R., Zhang, W., & Yang, X. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112509 · Cited by 4
Bizzotto, M., You, S. F., Tamborini, M., Faggiani, E., Morini, R., Borreca, A., Zhang, R., Aladyeva, E., Nallapu, A., Ferrari, C., et al. (2026) · Neuron · doi:10.1016/j.neuron.2026.04.043 · Cited by 5
Wang, H., Wen, R., Parker, E., & Yang, L. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03083-9 · Cited by 4
Pathophysiology of Alzheimer’s Disease: Focus on H3 Receptor Modulators and Their Implications
Bandaru, N., Bukke, S. P. N., Pedapati, V. M. D., Sowjanaya, G., Suggu, V. S., Nalla, S., Dudhe, P. B., Ezeonwumelu, J. O. C., Alagbonsi, A. I., & Onohuean, H. (2025) · Drugs and Drug Candidates · doi:10.3390/ddc4020022 · Cited by 4
TREM2 ‐Mediated Myeloid Cells Protect Against Pathological Choroidal Neovascularization
wang, T., Szczepan, M., Gregg, A. T., Wang, X., Smith, L. E. H., & Sun, Y. (2025) · The FASEB Journal · doi:10.1096/fj.202501793r · Cited by 4
He, S., Mittra, N., Bao, H., Bhattacharjee, A., Dodds, S. G., Dupree, J. L., & Han, X. (2026) · Nature Communications · doi:10.1038/s41467-025-66222-9 · Cited by 4
Alterations in the brain lipidome of Alzheimer's disease donors with rare TREM2 risk variants
Proitsi, P., Ebshiana, A., Wretlind, A., Xu, J., Hodges, A., & Legido‐Quigley, C. (2026) · Brain Communications · doi:10.1093/braincomms/fcaf452 · Cited by 5
Metadata
- Authors
- Wang, S., Mustafa, M., Yuede, C. M., Salazar, S. V., Kong, P., Long, H., Ward, M., Siddiqui, O., Paul, R., Gilfillan, S., Ibrahim, A., Rhinn, H., Tassi, I., Rosenthal, A., Schwabe, T., & Colonna, M.
- Affiliations
- Washington University in St. Louis (US)
- Alector (United States) (US)
- Corresponding author
- Schwabe, Tina
- Colonna, Marco
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-06-24
- Volume
- 217
- Issue
- 9
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7478730
- OpenAlex
- W3037497912
- Cited by
- 549
- References
- 41
- Citations by year
- 2026: 106 · 2025: 115 · 2024: 101 · 2023: 93 · 2022: 64 · 2021: 52 · 2020: 18
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (RF1AG05148501, R21 AG059176, RF1 AG059082)
- Cure Alzheimer’s Fund
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- TREM2, Alzheimer's disease, microglial proliferation, amyloid plaques, microglial inflammation, transgenic mouse model, single-cell RNA sequencing, cerebrospinal fluid biomarkers, immunotherapy
- MeSH terms
- Alzheimer Disease, Animals, Antibodies, Monoclonal, Anxiety, Blood-Brain Barrier, Disease Models, Animal, Humans, Membrane Glycoproteins, Mice, Inbred C57BL, Mice, Transgenic, Protein Conformation, Receptors, Immunologic, Solubility, Signal Transduction, Biomarkers, Amyloid beta-Peptides, Neurites, Microglia, Cell Proliferation, Osteopontin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.